Press Release
Digbi Health in the news
Featured Press
Digbi Health Launches an SEC-regulated Offering, Giving Millions the Opportunity to Invest in Groundbreaking Genetics and Gut Microbiome-based Care for Obesity and Digestive Health
Palo Alto, California, September 30, 2024 - Digbi Health, a leader in Precision Biology-based care for obesity, type 2 diabetes, and gastrointestinal health, is excited to announce its SEC-regulated raise. This initiative allows millions to invest in the company's mission to transform healthcare by expanding access to personalized, genetics-based, and gut microbiome-driven treatments. Opening Equity Participation and Expanding Access to Care For the first time, Digbi Health is offering equity participation to the public, democratizing an investment opportunity that was previously only available to venture capital firms. This SEC-regulated raise allows individuals to support Digbi Health's vision of making Precision Biology-driven care for obesity and digestive health accessible to millions by expanding insurance benefits and Medicare coverage. "By offering investment opportunity to the public, we are not only expanding ownership but also accelerating our commitment to making Precision Biology treatments available to millions," said Ranjan Sinha, CEO of Digbi Health. "Our goal is to integrate personalized, genetics and microbiome-based programs into everyday healthcare, expanding coverage through insurance and Medicare so more people can benefit from advanced, data-driven care." Transforming Health Care Through Innovation Thirty-five million users already have access to Digbi Health's personalized programs through major health plans and employers. With over $16 million in funding from leading venture capital firms, the company will further expand its reach. This Reg CF offering on StartEngine allows more individuals to support the company's groundbreaking work in bringing effective, personalized treatments for obesity and digestive health to millions. About Digbi Health Digbi Health pioneered Precision Biology, integrating gut microbiome, CGM, and genetics to holistically prevent and treat three of the top four most expensive healthcare conditions - Obesity, Cardiometabolic, and Digestive. Our innovative, proven approach is highly differentiated and resonates with employers and health plans seeking new ways to eliminate the scourge of point solutions and reduce healthcare costs, especially GLP-1-related drug costs. Our competitive edge lies in our unique data and bioinformatics platform, consolidating millions of diverse data points across genetics, progression of gut microbiome, metabolic, health, and disease markers. This repository empowers us to personalize care, unearth patentable signatures, generate impactful health risk profiles, and stratify patient care accurately for treatment. Digbi's unique contactable data set appeals to top pharmaceutical and food companies, positioning us as a leader in the field. This equity raise is being conducted in accordance with Regulation Crowdfunding (Reg CF), a provision enacted by Congress under the JOBS Act, and is fully compliant with the rules and regulations established by the U.S. Securities and Exchange Commission (SEC). For more information on the equity raise and how to invest, visit https://www.startengine.com/offering/digbi-health
Digbi Health Expands Its Employer Offering with the GLP-1 Obesity Management Solution Integrated Across Payer, PBM, Provider, and Employer
News Provided by Digbi Health July 22 2024 10:00 EST State Public Health Insurance Trust Partners with Digbi Health to Manage Obesity Treatment Costs Amid Rising GLP-1 Drug Expenses for its Municipal and Teachers Union Workers Mountain View, July 22, 2024 – A leading public health insurance trust has selected Digbi Health to manage the escalating costs and effective utilization of new GLP-1 weight-loss drugs. This partnership will leverage Digbi Health's proprietary Obesity Compass to provide effective and cost-efficient treatment plans for all its members. Due to the surge in demand for GLP-1 drugs, employers and health plans nationwide face uncertainty and significant cost increases. This partnership addresses these challenges by employing innovative solutions without compromising a member’s health. Key Highlights: Effective Cost Management:The initiative launched in June as a cost-containment strategy after unsustainable growth in GLP-1 medication usage and costs. Prior Authorization:Digbi Health will oversee the Prior Authorization for all weight management medications, using patented predictive modeling to determine the most effective and economical care modalities for members to achieve a healthy BMI. Holistic Solution: Digbi Health leverages genetics, gut microbiome, continuous glucose monitoring (CGM), and lab reports to provide personalized food and lifestyle support to all members on weight management medications. This approach addresses the underlying root causes of their conditions, related comorbidities, medication side effects, and, if recommended, medication tapering. Precision Biology is an innovative approach that uses an individual's genetic makeup, gut microbiome profile, and metabolic data to create highly personalized treatment plans. Precision Biology can identify the most effective dietary, lifestyle, and pharmacological interventions by analyzing a person's unique biological data. This method ensures that treatments are tailored to address the root causes of obesity and related conditions, resulting in more effective and sustainable health outcomes. “As the market struggles with finding an optimal strategy for weight management and GLP-1 cost containment, we aim to set new care standards by focusing on three key areas: enhancing member experiences through integrations, using Precision Biology to more accurately identify those who need medication support, and tackling the underlying root causes, comorbidities, and side effects. We look forward to successfully collaborating with employers, health plans, benefits consultants, and PBMs to deliver personalized, effective, and affordable care,” said Ranjan Sinha, Founder and CEO of Digbi Health. About Digbi Health: Digbi Health pioneered Precision Biology to treat obesity, T2 Diabetes, and digestive health by harnessing genetics and gut microbiome analysis. This innovative approach develops personalized "Food-As-Medicine" treatment plans, targeting the root causes of obesity and T2D. Digbi Health’s GLP Compass, developed working with Novo Nordisk and the University of Virginia Medical School, uses proprietary data and AI models to identify the most clinically effective and cost-efficient treatment paths.
Digbi Health Launches GLP-Fit™ Program: Expands its Precision Biology Platform to Incorporate GLP-1 based Personalized Care for Obesity
PALO ALTO, Calif., September 28, 2023 – (BUSINESS WIRE)-- Digbi Health, the leader in precision biology-based telehealth care for three of the top four healthcare costs - Obesity, T2D, and Digestive Health - announced today the launch of its latest innovation in obesity care, Digbi GLP-Fit™, a scientifically-backed approach to identify the best treatment path for an individual to prevent and treat obesity. Key Highlights: Digbi GLP-Fit™ uses the science of precision biology to identify the best treatment path for obesity for an individual with 87% accuracy, which may include 1) only precision nutrition, 2) a combination of precision nutrition and lower-cost drugs like Metformin, or 3) a combination of precision nutrition and GLP-1 medications. For Pharmacy Benefit Managers (PBMs), Digbi GLP-Fit™ streamlines prior authorization processes for GLP-1 obesity management drugs, eliminating member frustration, generating multi-million dollar savings, and creating goodwill for health plans and employers. Digbi GLP-Fit™ program guarantees 100% financial ROI, providing immediate and tangible savings for employers, PBMs, and health plans, all while ensuring optimal and medically safe patient care. The Science Behind Digbi GLP-Fit(™) This clinically proven approach integrates genetics, gut microbiome, and Continuous Glucose Monitoring (CGM) insights to recommend the best path for care and deliver personalized, clinically effective obesity treatment programs. Unlike other digital programs that rely exclusively on behavior change, Digbi GLP-Fit™ is based on recognition by the National Institutes of Health (NIH) and medical research institutions like Harvard Health that genetics account for up to 80% of the risk of obesity and that an individual's insulin resistance and gut-microbiome are essential factors in addressing obesity. Digbi GLP-Fit™ integrates telehealth and precision nutrition based on genetics, gut microbiome, and insulin metabolism. Sustainable, Effective, and High-Quality Care This personalized approach offers tremendous savings for employers and payers. Digbi's program ensures that individuals are not unnecessarily on lifelong GLP-1 treatments, aligning with Digbi Health's prevention and effective care mission. With a Google rating of 4.8 stars, Digbi Health stands out for its unwavering commitment to delivering a high-quality member experience. "We believe in the power of precision biology and full-spectrum obesity care, which includes anti-obesity medications only when necessary. Recognizing that everyone does not respond the same way to food and medicine, Digbi is committed to making obesity care personalized, preventive, and holistic," said Ranjan Sinha, CEO of Digbi Health. "Payers and employers want to partner with us because our unique approach delivers the best obesity solution that is clinically safe and financially sustainable.” Novo Nordisk's Global Prevention Accelerator Program recently selected Digbi to pilot-test solutions for preventing obesity and related cardiometabolic conditions. True Personalization: The 5-Point Digbi GLP-Fit™ Program Difference While other digital providers tout personalization, Digbi GLP-Fit delivers the following advanced capabilities: Precision Diagnostics: Incorporates genetics, gut microbiome, and Continuous Glucose Monitoring (CGM) to provide a comprehensive bio-digital twin view of an individual's health. Risk Assessment: Evaluate the patient's obesity risk embedded in their genetics, gut microbiome, and insulin metabolism. Three hundred gene variants are used to develop and monitor a polygenic risk score for weight regain. Precision Biology-Based Lifestyle Support: The FDA requires GLP drugs to have nutrition and lifestyle support. Proven and Patented De-prescription Path: Develops clinically safe, sustainable, personalized tapering off-plan for GLP drugs. Gut Microbiome Informed Care: GLP is a gut hormone that regulates appetite, metabolism, and insulin secretion. Recent studies have shown that the gut microbiome may play a role in the effectiveness of GLP-1 drugs. With Digbi GLP-Fit™, the gut microbiome is monitored every 120 days. A longer tapering period is considered if the gut microbiome has not shifted to a less obesogenic state. Media Contact: Beverly Ibarrolan; beverly@digbihealth.com About Digbi Health Digbi Health is leading through innovation, offering a holistic solution for treating Obesity, Cardiometabolic, and Digestive disorders—three of healthcare's top 4 costly conditions. Our Precision Biology approach uses genetics, gut microbiome, Abbott CGM, and pharmaceuticals only when necessary to create personalized care programs that slash medication dependency and healthcare costs. We are on a mission to make chronic illness optional. Learn more at: www.digbihealth.com
Latest Press
Digbi Health Launches an SEC-regulated Offering, Giving Millions the Opportunity to Invest in Groundbreaking Genetics and Gut Microbiome-based Care for Obesity and Digestive Health
Palo Alto, California, September 30, 2024 - Digbi Health, a leader in Precision Biology-based care for obesity, type 2 diabetes, and gastrointestinal health, is excited to announce its SEC-regulated raise. This initiative allows millions to invest in the company's mission to transform healthcare by expanding access to personalized, genetics-based, and gut microbiome-driven treatments. Opening Equity Participation and Expanding Access to Care For the first time, Digbi Health is offering equity participation to the public, democratizing an investment opportunity that was previously only available to venture capital firms. This SEC-regulated raise allows individuals to support Digbi Health's vision of making Precision Biology-driven care for obesity and digestive health accessible to millions by expanding insurance benefits and Medicare coverage. "By offering investment opportunity to the public, we are not only expanding ownership but also accelerating our commitment to making Precision Biology treatments available to millions," said Ranjan Sinha, CEO of Digbi Health. "Our goal is to integrate personalized, genetics and microbiome-based programs into everyday healthcare, expanding coverage through insurance and Medicare so more people can benefit from advanced, data-driven care." Transforming Health Care Through Innovation Thirty-five million users already have access to Digbi Health's personalized programs through major health plans and employers. With over $16 million in funding from leading venture capital firms, the company will further expand its reach. This Reg CF offering on StartEngine allows more individuals to support the company's groundbreaking work in bringing effective, personalized treatments for obesity and digestive health to millions. About Digbi Health Digbi Health pioneered Precision Biology, integrating gut microbiome, CGM, and genetics to holistically prevent and treat three of the top four most expensive healthcare conditions - Obesity, Cardiometabolic, and Digestive. Our innovative, proven approach is highly differentiated and resonates with employers and health plans seeking new ways to eliminate the scourge of point solutions and reduce healthcare costs, especially GLP-1-related drug costs. Our competitive edge lies in our unique data and bioinformatics platform, consolidating millions of diverse data points across genetics, progression of gut microbiome, metabolic, health, and disease markers. This repository empowers us to personalize care, unearth patentable signatures, generate impactful health risk profiles, and stratify patient care accurately for treatment. Digbi's unique contactable data set appeals to top pharmaceutical and food companies, positioning us as a leader in the field. This equity raise is being conducted in accordance with Regulation Crowdfunding (Reg CF), a provision enacted by Congress under the JOBS Act, and is fully compliant with the rules and regulations established by the U.S. Securities and Exchange Commission (SEC). For more information on the equity raise and how to invest, visit https://www.startengine.com/offering/digbi-health
Digbi Health Expands Its Employer Offering with the GLP-1 Obesity Management Solution Integrated Across Payer, PBM, Provider, and Employer
News Provided by Digbi Health July 22 2024 10:00 EST State Public Health Insurance Trust Partners with Digbi Health to Manage Obesity Treatment Costs Amid Rising GLP-1 Drug Expenses for its Municipal and Teachers Union Workers Mountain View, July 22, 2024 – A leading public health insurance trust has selected Digbi Health to manage the escalating costs and effective utilization of new GLP-1 weight-loss drugs. This partnership will leverage Digbi Health's proprietary Obesity Compass to provide effective and cost-efficient treatment plans for all its members. Due to the surge in demand for GLP-1 drugs, employers and health plans nationwide face uncertainty and significant cost increases. This partnership addresses these challenges by employing innovative solutions without compromising a member’s health. Key Highlights: Effective Cost Management:The initiative launched in June as a cost-containment strategy after unsustainable growth in GLP-1 medication usage and costs. Prior Authorization:Digbi Health will oversee the Prior Authorization for all weight management medications, using patented predictive modeling to determine the most effective and economical care modalities for members to achieve a healthy BMI. Holistic Solution: Digbi Health leverages genetics, gut microbiome, continuous glucose monitoring (CGM), and lab reports to provide personalized food and lifestyle support to all members on weight management medications. This approach addresses the underlying root causes of their conditions, related comorbidities, medication side effects, and, if recommended, medication tapering. Precision Biology is an innovative approach that uses an individual's genetic makeup, gut microbiome profile, and metabolic data to create highly personalized treatment plans. Precision Biology can identify the most effective dietary, lifestyle, and pharmacological interventions by analyzing a person's unique biological data. This method ensures that treatments are tailored to address the root causes of obesity and related conditions, resulting in more effective and sustainable health outcomes. “As the market struggles with finding an optimal strategy for weight management and GLP-1 cost containment, we aim to set new care standards by focusing on three key areas: enhancing member experiences through integrations, using Precision Biology to more accurately identify those who need medication support, and tackling the underlying root causes, comorbidities, and side effects. We look forward to successfully collaborating with employers, health plans, benefits consultants, and PBMs to deliver personalized, effective, and affordable care,” said Ranjan Sinha, Founder and CEO of Digbi Health. About Digbi Health: Digbi Health pioneered Precision Biology to treat obesity, T2 Diabetes, and digestive health by harnessing genetics and gut microbiome analysis. This innovative approach develops personalized "Food-As-Medicine" treatment plans, targeting the root causes of obesity and T2D. Digbi Health’s GLP Compass, developed working with Novo Nordisk and the University of Virginia Medical School, uses proprietary data and AI models to identify the most clinically effective and cost-efficient treatment paths.
Digbi Health Launches GLP-Fit™ Program: Expands its Precision Biology Platform to Incorporate GLP-1 based Personalized Care for Obesity
PALO ALTO, Calif., September 28, 2023 – (BUSINESS WIRE)-- Digbi Health, the leader in precision biology-based telehealth care for three of the top four healthcare costs - Obesity, T2D, and Digestive Health - announced today the launch of its latest innovation in obesity care, Digbi GLP-Fit™, a scientifically-backed approach to identify the best treatment path for an individual to prevent and treat obesity. Key Highlights: Digbi GLP-Fit™ uses the science of precision biology to identify the best treatment path for obesity for an individual with 87% accuracy, which may include 1) only precision nutrition, 2) a combination of precision nutrition and lower-cost drugs like Metformin, or 3) a combination of precision nutrition and GLP-1 medications. For Pharmacy Benefit Managers (PBMs), Digbi GLP-Fit™ streamlines prior authorization processes for GLP-1 obesity management drugs, eliminating member frustration, generating multi-million dollar savings, and creating goodwill for health plans and employers. Digbi GLP-Fit™ program guarantees 100% financial ROI, providing immediate and tangible savings for employers, PBMs, and health plans, all while ensuring optimal and medically safe patient care. The Science Behind Digbi GLP-Fit(™) This clinically proven approach integrates genetics, gut microbiome, and Continuous Glucose Monitoring (CGM) insights to recommend the best path for care and deliver personalized, clinically effective obesity treatment programs. Unlike other digital programs that rely exclusively on behavior change, Digbi GLP-Fit™ is based on recognition by the National Institutes of Health (NIH) and medical research institutions like Harvard Health that genetics account for up to 80% of the risk of obesity and that an individual's insulin resistance and gut-microbiome are essential factors in addressing obesity. Digbi GLP-Fit™ integrates telehealth and precision nutrition based on genetics, gut microbiome, and insulin metabolism. Sustainable, Effective, and High-Quality Care This personalized approach offers tremendous savings for employers and payers. Digbi's program ensures that individuals are not unnecessarily on lifelong GLP-1 treatments, aligning with Digbi Health's prevention and effective care mission. With a Google rating of 4.8 stars, Digbi Health stands out for its unwavering commitment to delivering a high-quality member experience. "We believe in the power of precision biology and full-spectrum obesity care, which includes anti-obesity medications only when necessary. Recognizing that everyone does not respond the same way to food and medicine, Digbi is committed to making obesity care personalized, preventive, and holistic," said Ranjan Sinha, CEO of Digbi Health. "Payers and employers want to partner with us because our unique approach delivers the best obesity solution that is clinically safe and financially sustainable.” Novo Nordisk's Global Prevention Accelerator Program recently selected Digbi to pilot-test solutions for preventing obesity and related cardiometabolic conditions. True Personalization: The 5-Point Digbi GLP-Fit™ Program Difference While other digital providers tout personalization, Digbi GLP-Fit delivers the following advanced capabilities: Precision Diagnostics: Incorporates genetics, gut microbiome, and Continuous Glucose Monitoring (CGM) to provide a comprehensive bio-digital twin view of an individual's health. Risk Assessment: Evaluate the patient's obesity risk embedded in their genetics, gut microbiome, and insulin metabolism. Three hundred gene variants are used to develop and monitor a polygenic risk score for weight regain. Precision Biology-Based Lifestyle Support: The FDA requires GLP drugs to have nutrition and lifestyle support. Proven and Patented De-prescription Path: Develops clinically safe, sustainable, personalized tapering off-plan for GLP drugs. Gut Microbiome Informed Care: GLP is a gut hormone that regulates appetite, metabolism, and insulin secretion. Recent studies have shown that the gut microbiome may play a role in the effectiveness of GLP-1 drugs. With Digbi GLP-Fit™, the gut microbiome is monitored every 120 days. A longer tapering period is considered if the gut microbiome has not shifted to a less obesogenic state. Media Contact: Beverly Ibarrolan; beverly@digbihealth.com About Digbi Health Digbi Health is leading through innovation, offering a holistic solution for treating Obesity, Cardiometabolic, and Digestive disorders—three of healthcare's top 4 costly conditions. Our Precision Biology approach uses genetics, gut microbiome, Abbott CGM, and pharmaceuticals only when necessary to create personalized care programs that slash medication dependency and healthcare costs. We are on a mission to make chronic illness optional. Learn more at: www.digbihealth.com
